Das kardiorenale Syndrom

Abstract

In patients with chronic cardio renal syndrome chronic heart disease coexists with chronic kidney disease and poses the patients to a specifically high risk for cardiovascular events and mortality. Treatment recommendations in this condition with a high level of evidence are sparse. Mainstay of therapy in cardiorenal syndrome is fluid metabolism control and stabilization of renal and cardiac function, which can basically been achieved by substances modifying the renin-angiotensin-aldosterone-system as well as diuretics. Noteworthy, despite inducing short-term decreases in renal function, inhibition of the RAAS and diuretic medication associate with the long-term improvements of outcome (so-called pseudo-worsening of renal function). The chronic cardiorenal syndrome calls for interdisciplinary care by both nephrologists and cardiologists in order to allow high-end patient care with a maximum of beneficial effect and a minimum of treatment-related side effects.

Die Bezeichnung der Erkrankung umfasst bereits ihre Besonderheit, nämlich die Interaktion zwischen Herz- und Nierenerkrankungen. Hierbei ist nachhaltig die Fähigkeit erschwert, den Elektrolyt- und Wasserhaushalt zu regulieren. KRS-Patienten sind Hochrisikopatienten, und ihre Therapie profitiert vom Fachwissen beider beteiligter Disziplinen, der Kardiologie und der Nephrologie. Wo jeweils die Schwerpunkte zu setzen sind, zeigt dieser Beitrag.

Schlüsselwörter

Herzinsuffizienz - chronische Niereninsuffizienz - Therapie - Verschlechterung der Nierenfunktion - Renin-Angiotensin-Aldosteron-System

Key words

heart failure - chronic kidney disease - treatment - worsening of renal function - renin-angiotensin-aldosterone-system

• Literatur

• 1 Lewis T. A Clinical Lecture on Paroxsymal Dyspnoea in Cardiorenal Patients with Secial reference to “Cardiac” and “Ureamic” Asthma. Brit Med Journal 1913
• 2 Nayor M, Larson MG, Wang N. et al. The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2017; 19: 615-623
• 3 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975
• 4 Matsushita K, van der Velde M, Astor BC. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081
• 5 Smith GL, Lichtman JH, Bracken MB. et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-1996
• 6 Damman K, Navis G, Voors AA. et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007; 13: 599-608
• 7 Testani JM, Kimmel SE, Dries DL. et al. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011; 4: 685-691
• 8 Covic A, Vervloet M, Massy ZA. et al. Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes Endocrinol 2018; 6: 319-331
• 9 House AA. Cardiorenal syndrome: new developments in the understanding and pharmacologic management. Clin J Am Soc Nephrol 2013; 8 (10) 1808-1815
• 10 Damman K, van Deursen VM, Navis G. et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53: 582-588
• 11 Verbrugge FH, Dupont M, Steels P. et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 2013; 62: 485-495
• 12 Polsinelli VB, Sinha A, Shah SJ. Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. Curr Heart Fail Rep 2017; 14 (06) 519-528
• 13 Yancy CW, Jessup M, Bozkurt B. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the ACCF/AHA Task Force on Clinical Practice Guidelines and the HFSA. J Card Fail 2017; 23: 628-651
• 14 Clark WF, Sontrop JM, Huang SH. et al. Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial. JAMA 2018; 319: 1870-1879
• 15 Doukky R, Avery E, Mangla A. et al. Impact of Dietary Sodium Restriction on Heart Failure Outcomes. JACC Heart Fail 2016; 4 (01) 24-35
• 16 Sanches Machado d’Almeida K, Ronchi Spillere S, Zuchinali P. et al. Mediterranean Diet and Other Dietary Patterns in Primary Prevention of Heart Failure and Changes in Cardiac Function Markers: A Systematic Review. Nutrients 2018; 10: E58
• 17 Dos Reis PG, Sanches Machado d’Almeida K. et al. Dietary Patterns in Secondary Prevention of Heart Failure: A Systematic Review. Nutrients 2018; 10 (07) E828 . doi:10.3390/nu10070828
• 18 Kerley CP. Dietary patterns and components to prevent and treat heart failure: a comprehensive review of human studies. Nutr Res Rev 2018; DOI: 10.1017/S0954422418000148.
• 19 Testani JM, Chen J, McCauley BD. et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122 (03) 265-272
• 20 Ouwerkerk W, Voors AA, Anker SD. et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 2017; 38: 1883-1890
• 21 Clark H, Krum H, Hopper I. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Eur J Heart Fail 2014; 16: 41-48
• 22 Palaka E, Leonard S, Buchanan-Hughes A. et al. Evidence in support of hyperkalaemia management strategies: A systematic literature review. Int J Clin Pract 2018; 72 (02) DOI: 10.1111/ijcp.13052.
• 23 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
• 24 Locatelli F, Barany P, Covic A. et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346-1359
• 25 Swedberg K, Young JB, Anand IS. et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368: 1210-1219
• 26 Brisco MA, Kimmel SE, Coca SG. et al. Prevalence and prognostic importance of changes in renal function after mechanical circulatory support. Circ Heart Fail 2014; 7: 68-75
• 27 Adelstein EC, Shalaby A, Saba S. Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. Pacing Clin Electrophysiol 2010; 33 (07) 850-859
• 28 Iadarola GM, Lusardi P, La M. et al. Peritoneal ultrafiltration in patients with advanced decompensated heart failure. J Nephrol 2013; 26 (21) 159-176